Hyderabad-based bio-pharmaceutical company Suven Life Sciences Limited has received five new product patents (two from Israel, and a patent each from Japan, China and New Zealand). These patents have been granted for New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of two (2) granted patents from Israel, eleven(11) granted patents from Japan, fifteen (15) product patents from China and twenty one (21) product patents from New Zealand. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
The current market capitalisation of Suven Life Sciences stands at Rs 2,812.94 crore.The company has reported a standalone sales of Rs 139.83 crore and a Net Profit of Rs 24.84 crore for the quarter ended Sep 2014.
#Suven Life secures five new Product Patents pic.twitter.com/PFf3HcGOfC
— Press Release Watch (@PrReleaseWatch) December 12, 2014
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of two (2) granted patents from Israel, eleven(11) granted patents from Japan, fifteen (15) product patents from China and twenty one (21) product patents from New Zealand. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
The current market capitalisation of Suven Life Sciences stands at Rs 2,812.94 crore.The company has reported a standalone sales of Rs 139.83 crore and a Net Profit of Rs 24.84 crore for the quarter ended Sep 2014.
